MA32045B1 - Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine - Google Patents

Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine

Info

Publication number
MA32045B1
MA32045B1 MA32552A MA32552A MA32045B1 MA 32045 B1 MA32045 B1 MA 32045B1 MA 32552 A MA32552 A MA 32552A MA 32552 A MA32552 A MA 32552A MA 32045 B1 MA32045 B1 MA 32045B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
water
soluble
salt
phenolphenyl
Prior art date
Application number
MA32552A
Other languages
Arabic (ar)
English (en)
Inventor
Bruno Paillard
Jean-Louis Avan
JOëL BOUGARET
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA32045B1 publication Critical patent/MA32045B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur une composition pharmaceutique stable consistant en un sel de vinflunine hydrosoluble et en au moins un diluant et un lubrifiant, ladite composition étant sous la forme d'un solide destiné à une administration orale. Le sel de vinflunine hydrosoluble est, de préférence, le ditartrate de vinflunine. La composition pharmaceutique est avantageusement sous la forme d'une capsule ou d'un comprimé. L'invention porte également sur un procédé de traitement d'une pathologie cancéreuse, comprenant l'administration orale de la composition pharmaceutique de l'invention.
MA32552A 2007-07-11 2010-01-25 Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine MA32045B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0756421A FR2918566B1 (fr) 2007-07-11 2007-07-11 Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
US97033407P 2007-09-06 2007-09-06
PCT/EP2008/058893 WO2009007388A1 (fr) 2007-07-11 2008-07-09 Composition pharmaceutique stable comprenant un sel de vinflunine hydrosoluble

Publications (1)

Publication Number Publication Date
MA32045B1 true MA32045B1 (fr) 2011-02-01

Family

ID=38868376

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32552A MA32045B1 (fr) 2007-07-11 2010-01-25 Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine

Country Status (21)

Country Link
US (1) US9173842B2 (fr)
EP (1) EP2187886A1 (fr)
JP (1) JP2010533139A (fr)
KR (1) KR20100047230A (fr)
CN (1) CN101730533B (fr)
AR (1) AR067499A1 (fr)
AU (1) AU2008274223A1 (fr)
BR (1) BRPI0814216A2 (fr)
CA (1) CA2695039A1 (fr)
CL (1) CL2008002005A1 (fr)
CO (1) CO6160316A2 (fr)
FR (1) FR2918566B1 (fr)
MA (1) MA32045B1 (fr)
NZ (1) NZ583040A (fr)
PA (1) PA8789101A1 (fr)
RU (1) RU2462248C2 (fr)
SA (1) SA08290417B1 (fr)
TN (1) TN2010000013A1 (fr)
TW (1) TW200914018A (fr)
WO (1) WO2009007388A1 (fr)
ZA (1) ZA201000335B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135856A2 (fr) * 2011-04-01 2012-10-04 Spectrum Pharmaceuticals, Inc. Vinorelbine à très faible dose pour le traitement du cancer
JP6062422B2 (ja) * 2012-03-29 2017-01-18 杏林製薬株式会社 カプセル製剤
PT4331607T (pt) 2015-12-02 2025-05-22 Nippon Shinyaku Co Ltd Composição farmacêutica sólida que contém 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}-n-(metil-sulfonil)acetamida
CN106994121B (zh) * 2016-01-26 2021-07-02 江苏恒瑞医药股份有限公司 一种用于治疗癌症的药物组合物
GB202100470D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558053A (en) 1983-12-21 1985-12-10 Eli Lilly And Company Naphthalene-1,5-disulfonate salts of dimeric indole-dihydroindole alkaloids
US5369094A (en) * 1990-11-29 1994-11-29 The Administrators Of The Tulane Educational Fund Polypeptide bombesin antagonists
FR2707988B1 (fr) 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
FR2759293B1 (fr) 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
FR2761990B1 (fr) * 1997-04-10 1999-06-25 Pf Medicament Derives halogenes antimitotiques d'alcaloides de vinca
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
AU2002213119A1 (en) 2000-10-13 2002-04-22 Bristol-Myers Squibb Company Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and vinorelbine and method of using the same
US6890558B2 (en) 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
ATE462419T1 (de) 2002-05-31 2010-04-15 Rp Scherer Technologies Llc Orale pharmazeutische zusammensetzung für weichkapseln mit vinorelbin und behandlungsverfahren
US20070232533A1 (en) * 2003-05-09 2007-10-04 Kazuo Umezawa Use of Vinca Alkaloids and Salts Thereof
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
CZ2004964A3 (cs) 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
WO2006040779A2 (fr) 2004-10-11 2006-04-20 Natco Pharma Limited Formule à matrice flottante gastrique à libération contrôlée contenant la substance imatinib
EP1830817B1 (fr) 2004-12-30 2013-01-02 Pierre Fabre Medicament Suspension solide stable d'un dérivé de vinca-alcaloïde et procédé de fabrication dudit dérivé
FR2880274B1 (fr) 2004-12-30 2007-04-13 Pierre Fabre Medicament Sa Dispersion solide stable d'un derive d'alcaloides de vinca et son procede de fabrication
FR2894966B1 (fr) * 2005-12-20 2008-03-14 Pierre Fabre Medicament Sa Nouvelle forme cristalline de la vinflunine
WO2009105937A1 (fr) 2008-02-29 2009-09-03 江苏豪森药业股份有限公司 Gélule molle de vinorelbine, son procédé de préparation et son application.

Also Published As

Publication number Publication date
US9173842B2 (en) 2015-11-03
TW200914018A (en) 2009-04-01
EP2187886A1 (fr) 2010-05-26
WO2009007388A1 (fr) 2009-01-15
RU2010103934A (ru) 2011-08-20
BRPI0814216A2 (pt) 2015-10-27
AU2008274223A1 (en) 2009-01-15
US20100196468A1 (en) 2010-08-05
CL2008002005A1 (es) 2009-06-26
ZA201000335B (en) 2010-10-27
CN101730533A (zh) 2010-06-09
FR2918566B1 (fr) 2009-10-09
JP2010533139A (ja) 2010-10-21
AR067499A1 (es) 2009-10-14
NZ583040A (en) 2012-03-30
PA8789101A1 (es) 2009-04-23
SA08290417B1 (ar) 2013-01-22
FR2918566A1 (fr) 2009-01-16
CO6160316A2 (es) 2010-05-20
KR20100047230A (ko) 2010-05-07
CN101730533B (zh) 2013-05-29
RU2462248C2 (ru) 2012-09-27
TN2010000013A1 (en) 2011-09-26
CA2695039A1 (fr) 2009-01-15

Similar Documents

Publication Publication Date Title
MA57908B1 (fr) Composés macrocycliques substitués et méthodes de traitement associées
MA57825B1 (fr) Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
MA28748B1 (fr) Applications galeniques de melanges auto-emulsionnants d'excipients lipidiques
MA32045B1 (fr) Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
LU92275I2 (fr) 4-Aminopyridine ou un dérivé de celui-ci, spécialement un sel, un solvant ou une prodrogue
MA52219B1 (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27153A1 (fr) Formulations pharmaceutiques de derives de platine
BR0107565A (pt) Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas
HUP0002224A1 (hu) Virusellenes hatású benzimidazol-származékok
BR0014003A (pt) Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale
FR2918571B1 (fr) Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales
MA32056B1 (fr) Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene
MA33060B1 (fr) Formulations galéniques de composés organiques
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
BRPI0418384A (pt) composições farmacêuticas e métodos referentes à inibição de adesões fibrosas utilizando diversos agentes
ES2052732T3 (es) 2',3'-didesoxi-3'-fluorotimidina y compuestos afines para el tratamiento de infecciones por adenovirus.
MA27021A1 (fr) Sel consistant en citrate de 5,8,14-triazatetracyclo(10.3.1.0 .0 ) -hexadeca-2(11),3,5,7,9- pentaene et compositions pharmaceutiques le contenant
EP4027815A4 (fr) Compositions comprenant de la cytisine dans le traitement et/ou la prévention de l'addiction chez des sujets en ayant besoin
Fulmer et al. Development of antimicrobial peptides (AMPs) for use in self-decontaminating coatings